Yahoo Finance10d
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
ONS-5010 demonstrated noninferiority to ranibizumab at week 12 in the NORSE EIGHT trial. Based on the completed analysis of the 12-week results, Outlook Therapeutics plans to resubmit the ...
Nasdaq10d
Outlook Therapeutics Reports Positive 12-Week Results for ONS-5010 in Wet AMD Non-Inferiority Trial and Plans BLA Resubmission for 2025
ONS-5010 demonstrated noninferiority to ranibizumab at week 12 in the NORSE EIGHT trial. Based on the completed analysis of the 12-week results, Outlook Therapeutics plans to resubmit the ...
Nasdaq10d
Outlook's ONS-5010 Shows Non-Inferiority To Ranibizumab In NORSE EIGHT Trial
(RTTNews) - Outlook Therapeutics, Inc. (OTLK), a biopharmaceutical company, on Thursday announced the completion of the 12-week efficacy and safety results from its NORSE EIGHT clinical trial for ...
Business Insider4d
Promising Outlook for Exelixis’s Zanza: Strong Trial Results and Financial Prospects Support Buy Rating
The data from the Phase 1 STELLAR-001 trial indicates that the combination ... another drug in their pipeline, the overall outlook for Zanza remains positive. This optimistic view is further ...